从Malbranchea flocciformisis中分离出来的一种三度人体酸的抗糖尿病潜力
Daniela Rebollar-Ramos1, Berenice Ovalle-Magallanes1, Huzefa A Raja2
1Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, México.
Chemistry & biodiversity
|December 15, 2023
概括
来自Malbranchea flocciformis的一种新型,化合物3,显示出胰岛素性作用,在小鼠和细胞模型中可能起到胰岛素敏感剂和分泌剂的作用.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 菌类学 菌类学是指菌类学.
背景情况:
- 马尔布兰切亚 (Malbranchea flocciformis) ATCC 34530产生各种代谢物.
- 甲基酸是众所周知的多种生物活动.
研究的目的:
- 从M. flocciformis.中分离和表征代谢物.
- 为了研究化合物3的胰岛素和低血糖特性.
主要方法:
- 用有机提取方法分离和净化代谢物.
- 通过合成和X射线衍射分析阐明结构.
- 在体内研究 (口服葡萄糖耐受性测试,低血糖检测) 和在体内研究 (INS-1E细胞胰岛素分泌).
主要成果:
- 化合物3是一种三聚类人体酸,被分离出来,其结构得到了确认.
- 化合物3表现出胰岛素特质,减少小鼠的食后葡萄糖峰值.
- 它增强了INS-1E细胞中葡萄糖诱导的胰岛素分泌,表明其作为胰岛素敏感剂和非经典分泌剂的作用.
结论:
- 化合物3具有显著的胰岛素和低血糖活性.
- 这些发现支持其作为葡萄糖调节治疗剂的潜力.
- 遗传学分析证实了这种真菌菌株与Malbrancheaceae的关系.
相关概念视频
Glucagon-like Receptor Agonists
327
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
327
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179


